PCOS: Symptoms, Diagnosis & Evidence-Based Treatment Options

Polycystic ovary syndrome is a hormonal condition that affects how the ovaries function. Despite its name, PCOS is not primarily about cysts on the ovaries. The small follicles visible on ultrasound are actually immature egg-containing follicles that have not completed the ovulation process, not true cysts. The name, while established, can be misleading.

At its core, PCOS involves a combination of hormonal imbalances that can include elevated levels of androgens (often called male hormones, though they are present in all women), irregular or absent ovulation, and metabolic dysfunction, particularly insulin resistance. The underlying mechanisms are complex and likely involve genetic predisposition, environmental factors, and interactions between the reproductive and metabolic systems.

PCOS presents differently in different individuals. Some may have irregular periods and acne but normal weight, while others may struggle with weight gain and hair loss but have relatively regular cycles. This variability is one reason PCOS is frequently missed or misdiagnosed.

The symptoms of PCOS are diverse and can affect nearly every aspect of a person's health. Irregular menstrual cycles are the most common feature, with periods occurring more than 35 days apart, fewer than eight cycles per year, or absent periods altogether. Some individuals experience heavy or prolonged bleeding when a period does occur, as the uterine lining builds up over extended periods without ovulation.

Excess androgen effects include acne, particularly along the jawline and chin, hirsutism (excess hair growth on the face, chest, abdomen, or back), and androgenic alopecia (thinning hair on the scalp, especially at the crown). These symptoms can be emotionally distressing and are often the reason individuals first seek medical attention.

Weight gain or difficulty losing weight affects approximately 40 to 80 percent of individuals with PCOS, often concentrated around the abdomen. However, it is important to note that PCOS occurs across all body types, and approximately 20 to 30 percent of individuals with PCOS are of normal weight.

Other common symptoms include skin darkening in body folds (acanthosis nigricans, a sign of insulin resistance), skin tags, fatigue, mood changes including higher rates of anxiety and depression, and difficulty conceiving. The psychological impact of PCOS should not be underestimated, as the combination of visible symptoms and chronic management can significantly affect mental health.

Research shows that individuals with PCOS see an average of three or more healthcare providers over a period of more than two years before receiving a correct diagnosis. This diagnostic delay occurs for several reasons: the symptoms are often addressed in isolation (acne by a dermatologist, irregular periods by a gynecologist, weight concerns by a primary care provider), the condition presents differently across individuals, and there is no single definitive test.

The internationally accepted Rotterdam criteria require the presence of at least two of the following three features for diagnosis: oligo-ovulation or anovulation (irregular or absent ovulation, usually reflected in irregular periods), clinical or biochemical signs of elevated androgens (such as acne, hirsutism, or elevated testosterone levels on blood work), and polycystic ovarian morphology on ultrasound (12 or more follicles measuring 2 to 9 mm in one ovary, or an ovarian volume greater than 10 mL).

Importantly, other conditions that can mimic PCOS must be excluded before the diagnosis is made. These include thyroid disorders, congenital adrenal hyperplasia, Cushing syndrome, and hyperprolactinemia. Your provider will typically order blood tests including thyroid function, prolactin, and 17-hydroxyprogesterone to rule out these conditions.

A pelvic ultrasound is helpful but not required for diagnosis if the other two criteria are met. In adolescents, the diagnosis can be particularly challenging, as irregular periods and acne are common during normal puberty.

PCOS is fundamentally a metabolic condition. Insulin resistance, in which the body's cells do not respond effectively to insulin, is present in an estimated 50 to 70 percent of individuals with PCOS, including many who are of normal weight. This insulin resistance drives many of the hormonal imbalances seen in PCOS, as elevated insulin levels stimulate the ovaries to produce excess androgens.

The metabolic consequences of PCOS are significant. Individuals with PCOS have a 4 to 7 times higher risk of developing type 2 diabetes compared to age-matched women without PCOS. Prediabetes and impaired glucose tolerance are common even in young adults with the condition. Current guidelines recommend screening for glucose intolerance at the time of diagnosis and every one to three years thereafter, regardless of weight.

Cardiovascular risk factors are also more prevalent in PCOS. These include dyslipidemia (elevated triglycerides and LDL cholesterol, reduced HDL cholesterol), central obesity, chronic low-grade inflammation, and endothelial dysfunction. The American Heart Association has identified PCOS as a risk factor for cardiovascular disease, and long-term cardiovascular monitoring is recommended.

Additionally, individuals with PCOS who are not ovulating regularly may develop endometrial hyperplasia (thickening of the uterine lining) due to unopposed estrogen stimulation, which can increase the risk of endometrial cancer if left untreated. Ensuring regular menstrual shedding, either naturally or with medication, is an important part of PCOS management.

Treatment for PCOS is tailored to the individual's symptoms, health risks, and reproductive goals. There is no cure for PCOS, but the condition can be effectively managed.

Lifestyle modifications are the foundation of PCOS management for all individuals. Research shows that even a modest weight loss of 5 to 10 percent of body weight can improve insulin sensitivity, restore ovulatory cycles, reduce androgen levels, and improve fertility. A balanced diet emphasizing whole grains, lean proteins, vegetables, and healthy fats, combined with regular physical activity (at least 150 minutes of moderate exercise per week), is recommended. There is no single best diet for PCOS, but diets that reduce refined carbohydrates and added sugars tend to be most beneficial due to the role of insulin resistance.

Hormonal contraceptives (combined oral contraceptive pills, the patch, or the ring) are a first-line treatment for managing irregular periods, reducing androgen levels, treating acne and hirsutism, and protecting the endometrium from hyperplasia. They do not address the underlying metabolic issues but are effective for symptom management.

Spironolactone is an anti-androgen medication commonly used to treat persistent acne and hirsutism that does not respond adequately to hormonal contraceptives alone. It must be used with reliable contraception, as it can cause birth defects. Effects on hair growth typically take four to six months to become noticeable.

Metformin, an insulin-sensitizing medication traditionally used for type 2 diabetes, is used in PCOS to improve insulin resistance, which can help restore ovulatory cycles and reduce androgen levels. It is particularly useful for individuals with evidence of insulin resistance or glucose intolerance.

PCOS is the most common cause of anovulatory infertility, but the majority of individuals with PCOS can conceive with appropriate treatment. Letrozole (an aromatase inhibitor) is now the recommended first-line medication for ovulation induction in PCOS, having replaced clomiphene citrate based on evidence of higher ovulation and live birth rates. If oral medications are unsuccessful, injectable gonadotropins or in vitro fertilization (IVF) may be considered.

Individuals with PCOS undergoing fertility treatment should be monitored carefully, as they have a higher risk of ovarian hyperstimulation syndrome (OHSS), a potentially serious complication of ovarian stimulation.

One of the most exciting areas of emerging research in PCOS involves GLP-1 receptor agonists, a class of medications originally developed for type 2 diabetes and obesity. Early clinical data suggest that these medications may improve insulin resistance, promote weight loss, reduce androgen levels, and potentially restore ovulatory function in individuals with PCOS. While these medications are not yet FDA-approved specifically for PCOS, several clinical trials are underway, and some providers are using them off-label in selected patients. This is a rapidly evolving area, and new evidence is expected in the coming years.

Other areas of active research include the role of the gut microbiome in PCOS, anti-Mullerian hormone (AMH) as a diagnostic and monitoring tool, and inositol supplementation (a B-vitamin derivative) for improving insulin signaling.

A common misconception is that PCOS resolves with menopause. While some symptoms, such as irregular periods and acne, may improve as hormone levels change, the metabolic aspects of PCOS persist and may worsen with age. Insulin resistance, dyslipidemia, and cardiovascular risk factors do not disappear at menopause.

During perimenopause, individuals with PCOS may experience changes in their symptom profile. Menstrual cycles may become more regular for some, while others may experience heavier or more unpredictable bleeding. Androgen levels typically decline with age but may remain relatively elevated compared to women without PCOS.

Long-term management for individuals with PCOS should include regular screening for type 2 diabetes, lipid monitoring, blood pressure checks, cardiovascular risk assessment, and mental health support. Maintaining a healthy lifestyle with regular physical activity and a balanced diet remains important throughout life.

If you have been diagnosed with PCOS, ensure that all of your healthcare providers are aware of the diagnosis, not just your gynecologist. PCOS is a lifelong condition that benefits from coordinated, multidisciplinary care.